Treatment of chronic kidney diseases with histone deacetylase inhibitors

Histone deacetylases (HDACs) induce deacetylation of both histone and non-histone proteins and play a critical role in the modulation of physiological and pathological gene expression. Pharmacological inhibition of HDAC has been reported to attenuate progression of renal fibrogenesis in obstructed k...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Na, Zhuang, Shougang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411966/
https://www.ncbi.nlm.nih.gov/pubmed/25972812
http://dx.doi.org/10.3389/fphys.2015.00121
_version_ 1782368578384691200
author Liu, Na
Zhuang, Shougang
author_facet Liu, Na
Zhuang, Shougang
author_sort Liu, Na
collection PubMed
description Histone deacetylases (HDACs) induce deacetylation of both histone and non-histone proteins and play a critical role in the modulation of physiological and pathological gene expression. Pharmacological inhibition of HDAC has been reported to attenuate progression of renal fibrogenesis in obstructed kidney and reduce cyst formation in polycystic kidney disease. HDAC inhibitors (HDACis) are also able to ameliorate renal lesions in diabetes nephropathy, lupus nephritis, aristolochic acid nephropathy, and transplant nephropathy. The beneficial effects of HDACis are associated with their anti-fibrosis, anti-inflammation, and immunosuppressant effects. In this review, we summarize recent advances on the treatment of various chronic kidney diseases with HDACis in pre-clinical models.
format Online
Article
Text
id pubmed-4411966
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44119662015-05-13 Treatment of chronic kidney diseases with histone deacetylase inhibitors Liu, Na Zhuang, Shougang Front Physiol Physiology Histone deacetylases (HDACs) induce deacetylation of both histone and non-histone proteins and play a critical role in the modulation of physiological and pathological gene expression. Pharmacological inhibition of HDAC has been reported to attenuate progression of renal fibrogenesis in obstructed kidney and reduce cyst formation in polycystic kidney disease. HDAC inhibitors (HDACis) are also able to ameliorate renal lesions in diabetes nephropathy, lupus nephritis, aristolochic acid nephropathy, and transplant nephropathy. The beneficial effects of HDACis are associated with their anti-fibrosis, anti-inflammation, and immunosuppressant effects. In this review, we summarize recent advances on the treatment of various chronic kidney diseases with HDACis in pre-clinical models. Frontiers Media S.A. 2015-04-28 /pmc/articles/PMC4411966/ /pubmed/25972812 http://dx.doi.org/10.3389/fphys.2015.00121 Text en Copyright © 2015 Liu and Zhuang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Liu, Na
Zhuang, Shougang
Treatment of chronic kidney diseases with histone deacetylase inhibitors
title Treatment of chronic kidney diseases with histone deacetylase inhibitors
title_full Treatment of chronic kidney diseases with histone deacetylase inhibitors
title_fullStr Treatment of chronic kidney diseases with histone deacetylase inhibitors
title_full_unstemmed Treatment of chronic kidney diseases with histone deacetylase inhibitors
title_short Treatment of chronic kidney diseases with histone deacetylase inhibitors
title_sort treatment of chronic kidney diseases with histone deacetylase inhibitors
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411966/
https://www.ncbi.nlm.nih.gov/pubmed/25972812
http://dx.doi.org/10.3389/fphys.2015.00121
work_keys_str_mv AT liuna treatmentofchronickidneydiseaseswithhistonedeacetylaseinhibitors
AT zhuangshougang treatmentofchronickidneydiseaseswithhistonedeacetylaseinhibitors

Ejemplares similares